 second primari cancer hodgkin diseas updat result italian multicentr studi risk second primari cancer spc patient hodgkin diseas HD period januari decemb median follow-up seri year rang treatment categori radiotherapi RT patient chemotherapi cht patient RT cht patient salvag treatment resist HD patient fifty-six spc year initi treatment secondari acut nonlymphoid leukemia s-anll frequent spc case secondari non-hodgkin lymphoma s-nhl patient secondari solid tumor s-st patient calcul actuari risk SE spc year treatment modal s-anll risk case radiotherapi group cht RT salvag group actuari risk fact year former group latter signific differ cht RT group cht RT group relationship chemotherapeut regimen s-anll case mechlorethamin vincristin procarbazin prednison mopp RT group case group doxorubicin bleomycin vinblastin dacarbazin abvd RT signific differ s-anll actuari risk patient mopp RT treatment group respect s-st actuari risk year signific differ group differ modal data multivari analysi treatment modal age independ variabl s-anll s-st develop prolong follow-up analysi actuari spc risk year real spc incid seri